Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17959004 | 0.97 | CA12 (0.49) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL23457849 | 0.93 | CA12 (0.48) | CA12CA1CA2CA9AAK1 | |
| SCHEMBL20472087 | 0.91 | CA12 (0.47) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL20471820 | 0.90 | CA12 (0.48) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL3197902 | 0.87 | CA12 (0.54) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL20471909 | 0.87 | CA12 (0.46) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL2551702 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25840614 | 0.86 | CA12 (0.54) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL2548980 | 0.85 | CA12 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12514969 | 0.84 | CA12 (0.54) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580224-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3580224-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11168095-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2018148204-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2018-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168095-B2 | ASK1 inhibiting agents | MAP3K1, MAP3K10, MAP3K20 | CA12 4819/4885CA1 3842/4885CA2 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.